Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
Lloyd Paul Aiello(Joslin Diabetes Center), Lois E. H. Smith(Boston Children's Hospital), Eric A. Pierce(Massachusetts Eye and Ear Infirmary), L Riddle(Massachusetts Eye Research and Surgery Institute), Hui Chen(Massachusetts Eye Research and Surgery Institute), Napoleone Ferrara(Unknown), E D Foley(Massachusetts Eye Research and Surgery Institute), Hitoshi Takagi(St. Marianna University School of Medicine), George L. King(Joslin Diabetes Center)
Cited by 1,267
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
|Endocrine Reviews|2004|3.7k
Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway
|Journal of Biological Chemistry|1998|2k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k